Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


March 30, 2015 10:35 AM ET

Biotechnology

Company Overview of Genocea Biosciences, Inc.

Company Overview

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel vaccines and immunotherapies to treat infectious diseases. The company uses its proprietary discovery platform, AnTigen Lead Acquisition System, to design vaccines and immunotherapies that act through T cell immune responses. Its lead product candidate is GEN-003, a therapeutic vaccine or immunotherapy that is in Phase II trials to treat genital herpes infections. It is also developing GEN-004, a Phase II vaccine for the prevention of pneumococcal infections; GEN-001 that is in pre-clinical product candidate for treating chlamydia prophylaxis; GEN-002, which is in pre-clinical stage for the treatment of HSV-...

100 Acorn Park Drive

5th Floor

Cambridge, MA 02140

United States

Founded in 2006

57 Employees

Phone:

617-876-8191

Key Executives for Genocea Biosciences, Inc.

Chief Executive Officer, President and Director
Age: 45
Total Annual Compensation: $393.6K
Chief Financial Officer
Age: 39
Total Annual Compensation: $285.2K
Chief Medical Officer
Age: 62
Total Annual Compensation: $366.1K
Senior Vice President of Research
Age: 42
Total Annual Compensation: $238.3K
Compensation as of Fiscal Year 2014.

Genocea Biosciences, Inc. Key Developments

Genocea Biosciences, Inc. Appoints Michael Higgins as Directors

Genocea Biosciences, Inc. announced that Michael Higgins has joined the company's board of directors. Mr. Higgins is an experienced biotechnology executive and is currently entrepreneur-in-residence at Polaris Venture Partners. He previously served as chief operating officer and chief financial officer at Ironwood Pharmaceuticals from 2003 to 2014.

Genocea Biosciences, Inc. Reports Unaudited Financial Results for the Fourth Quarter and Year Ended December 31, 2014

Genocea Biosciences, Inc. reported unaudited financial results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported grant revenue of $0.308 million against $0.020 million a year ago. Loss from operations was $10.926 million against $6.169 million a year ago. Net loss was $11.650 million against $6.346 million a year ago. Net loss per basic and diluted share attributable to common stockholders was $0.66 against $22.50 a year ago. For the year, the company reported grant revenue of $0.308 million against $0.731 million a year ago. Loss from operations was $33.166 million against $19.925 million a year ago. Net loss was $35.296 million against $20.806 million a year ago. Net loss per basic and diluted share attributable to common stockholders was $2.27 against $75.46 a year ago.

Genocea Biosciences, Inc., Q4 2014 Earnings Call, Feb 12, 2015

Genocea Biosciences, Inc., Q4 2014 Earnings Call, Feb 12, 2015

Similar Private Companies By Industry

Company Name Region
Trophos Energy, Inc. United States
Seragen, Inc. United States
Aviva Systems Biology LLC United States
Advanced AgriTraits LLC United States
Calibrant Biosystems, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
November 20, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Genocea Biosciences, Inc., please visit www.genocea.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.